Merck & Co., Inc. (MRK) Reports Positive Topline Results from its Phase 3 CORALreef Lipids Trial

Merck & Co., Inc. (NYSE:MRK) is included in our list of the 11 Best Roth IRA Stocks to Invest in Now.

Merck & Co., Inc. (NYSE:MRK) showcased the potential of enlicitide decanoate, an investigational oral PCSK9 inhibitor for hypercholesterolemia. It did so by reporting positive topline results from its Phase 3 CORALreef Lipids trial on September 2, 2025.

The study met all the endpoints, with enlicitide delivering significant reductions in LDL-C, non-HDL-C, ApoB, and Lp(a) compared to placebo at Week 24. Furthermore, the study reported favorable safety outcomes, with low discontinuation rates and no meaningful differences in adverse events between treatment groups. The results follow the previous momentum achieved with successful outcomes, reinforcing its promise as the first oral macrocyclic peptide PCSK9 inhibitor. The achievement positions Merck & Co., Inc. (NYSE:MRK) to seek regulatory review and potentially redefine cholesterol management.

Merck & Co., Inc. (NYSE:MRK), a global biopharmaceutical company, focuses on developing innovative medicines, vaccines, and health solutions to save and improve lives worldwide. It is one of the Best Roth IRA Stocks.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 10 Must-Buy Canadian Stocks to Invest in.

Disclosure: None.